CBO projects Senate drug pricing bill would cut the development of 10 drugs over 30 years
The Congressional Budget Office on Friday said that Senate Democrats’ proposal to allow Medicare to negotiate certain drug prices could lower the federal deficit by about $288 billion through 2031, and reduce drugmakers’ 1,300 total drug approvals by about 10 drugs over the next three decades.
That trade-off, part of a larger Senate reconciliation package only needing a simple majority of votes to pass, finds a middle ground among the other recent Congressional attempts to stem rising drug prices.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.